PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
40591130,Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial.,2025,Diya; Gayed; Lowry; Ma; Bangad; Mensa; Zou; Xie; Hu; Cutler; Belanger; Cooper; Xu; Mogg; Türeci; Şahin; Swanson; Modjarrad; Anderson; Gurtman; Kitchin,"Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.; Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.; Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.; Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.; Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.; Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.; Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.",juleen.gayed@pfizer.com
40357526,Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis.,2025,Fahrbach; Cichewicz; Chu; Di Fusco; Burnett; Volkman; Akin-Fajiye; Mendoza; Cappelleri,"Evidence Synthesis, Evidera Inc., Wilmington, NC, USA.; Evidence Synthesis, Evidera Inc., Wilmington, NC, USA.; Statistics, Pfizer Inc., New York, NY, USA.; Health Economics and Outcomes Research, Pfizer Inc., New York, NY, USA.; Evidence Synthesis, Evidera Inc., Wilmington, NC, USA.; Medical Affairs, Pfizer Inc., New York, NY, USA.; Evidence Synthesis, Evidera Inc., Wilmington, NC, USA.; Health Economics and Outcomes Research, Pfizer Inc., New York, NY, USA.; Statistics, Pfizer Inc., New York, NY, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Lloyd; Smith; Gruber; Ondari; Wong; Hu; Clarke; McEvoy; Amend; Beachler; McMahill-Walraven; Seeger; Secora; Djibo; Song; Selvam; DeShazo; Clifford; Abente; Chillarige; Forshee; Anderson; Shoaibi,"Acumen LLC, Burlingame, California, USA.; Acumen LLC, Burlingame, California, USA.; Acumen LLC, Burlingame, California, USA.; Acumen LLC, Burlingame, California, USA.; Acumen LLC, Burlingame, California, USA.",
40301395,Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System.,2025,Appaneal; Lopes; Puzniak; Zasowski; Jodar; McLaughlin; Caffrey,"Pfizer Inc., New York, NY, US.; Pfizer Inc., New York, NY, US.; Pfizer Inc., New York, NY, US.; Pfizer Inc., New York, NY, US.",Aisling_Caffrey@uri.edu; Aisling_Caffrey@uri.edu; Aisling_Caffrey@uri.edu; Aisling_Caffrey@uri.edu
40240603,Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines.,2025,Krawczyk; Mazur; Orzeł; Gewartowska; Jeleń; Antczak; Kasztelan; Brouze; Matylla-Kulińska; Gumińska; Tarkowski; Owczarek; Affek; Turowski; Tudek; Sroka; Śpiewla; Kusio-Kobiałka; Wesołowska; Nowis; Golab; Kowalska; Jemielity; Dziembowski; Mroczek,"ExploRNA Therapeutics, Warsaw, Poland.",adziembowski@iimcb.gov.pl; adziembowski@iimcb.gov.pl; s.mroczek2@uw.edu.pl; s.mroczek2@uw.edu.pl
